Oncolytics Biotech secures pelareorep patent
Analysis based on 6 articles · First reported Jun 16, 2026 · Last updated Jun 16, 2026
The issuance of a new patent to Oncolytics Biotech for its pelareorep manufacturing process is expected to positively impact the company's stock price by securing its intellectual property and supporting future commercialization. This strengthens the long-term value proposition of Oncolytics Biotech's lead product, pelareorep, in the biotechnology market.
Oncolytics Biotech announced that the United States — United States Patent and Trademark Office has issued a new patent protecting the company's proprietary manufacturing process for pelareorep. This patent is expected to provide intellectual property protection until 2044, ensuring Oncolytics Biotech's ability to produce pelareorep at a commercial scale. Additionally, a previously filed method-of-use patent application for pelareorep's use as an immunotherapy is under review, potentially offering protection until 2046. Oncolytics Biotech also plans to file further patent applications in 2026 to expand its intellectual property estate for pelareorep across various therapeutic applications and treatment settings. Jared Kelly, CEO of Oncolytics Biotech, emphasized the importance of a strong intellectual property estate for the program's advancement toward registration and commercialization.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard